부산대학교 도서관

In this article, the authors review current literature to analyze the cost-effectiveness of seven vaccines now available for adolescents and one that is in development. An analysis is also performed regarding the cutoff price that deems a vaccine “cost-effective.” Often, $50,000 is the limit below which a drug is viewed as cost-effective. Our article contends that $160,000 could be a new limit below which the cost-effectiveness of a vaccine is better reflected. Based on standard economic valuations of life years in the United States and the preponderance of evidence from the cost-effectiveness literature, there is a compelling case for expanding adolescent vaccine programs, guidelines, and educational initiatives in the United States; there exist considerable economic benefits in excess of costs from policies that may achieve this objective. [ABSTRACT FROM AUTHOR]